Attached files
file | filename |
---|---|
8-K - FORM 8-K - MCKESSON CORP | f57720e8vk.htm |
Exhibit 99.1
Contacts:
Investors
Ana Schrank
ana.schrank@McKesson.com
415-983-7153
Ana Schrank
ana.schrank@McKesson.com
415-983-7153
Media
Kris Fortner
kris.fortner@McKesson.com
415-983-8352
Kris Fortner
kris.fortner@McKesson.com
415-983-8352
McKesson Completes Acquisition of US Oncology
Organization provides industry-leading offerings for community oncology
SAN FRANCISCO, December 30, 2010 McKesson Corporation (NYSE: MCK), a leading healthcare
services and information technology company, today announced that it has completed its acquisition
of US Oncology, a leading integrated oncology company that serves one of the nations largest
networks of community-based oncologists.
With the completion of the acquisition, initially announced on November 1, McKesson now delivers
one of the most comprehensive sets of oncology practice-management offerings in the country to help
strengthen the financial performance of community oncologists, advance the science of cancer care
and provide the highest quality care for patients.
Today marks a significant milestone in our vision for advancing the success of community
oncology, said John H. Hammergren, chairman and chief executive officer, McKesson Corporation. We
are pleased to welcome US Oncologys customers and employees to McKesson. The unified organization
will provide oncology practices with access to a robust suite of business, clinical and
supply-chain solutions that will help enhance the health and vitality of community-based oncology
and improve the quality and cost-effectiveness of patient care.
McKesson now offers community oncologists one of the industrys broadest arrays of technology,
pharmaceutical distribution, reimbursement, research and clinical services, as well as the
continued flexibility to select the business-relationship model that best meets their needs.
Oncologists will have the option of selecting from a wide range of products and services, such as
specialty distribution or inventory-management solutions, or choosing to become a comprehensive
strategic alliance (CSA) customer, which provides technology, practice-management services, and
other resources and expertise designed to help community oncologists achieve long-term success.
The combined business will be led by Bruce Broussard, chief executive officer of US Oncology, and
will be headquartered in The Woodlands, Texas, with continuing operations in the San Francisco Bay
Area and other locations throughout the country. Broussard reports to Paul Julian, executive vice
president and group president, McKesson Corporation.
The total transaction, including the assumption or repayment of the outstanding debt of US Oncology
and its subsidiaries, was valued at approximately $2.2 billion. The cash consideration paid by
McKesson at the merger closing was approximately $415 million. Immediately prior to the closing, US
Oncology Holdings, Inc. called all of its outstanding Senior Unsecured Floating Rate Toggle Notes
due 2012 for redemption, and US Oncology, Inc. called all of its outstanding 9.125% Senior Secured
Notes due 2017 and 10.75% Senior Subordinated Notes due 2014 for redemption, which is expected to
occur on January 31, 2011 for the Senior Unsecured Floating Rate Toggle Notes, February 16, 2011
for the 9.125% Senior Secured Notes and February 17, 2011 for the 10.75% Senior Subordinated Notes.
The aggregate redemption payment for the notes is estimated to be approximately $1.79 billion,
including the principal amounts, accrued and unpaid interest, and associated redemption premiums.
However, the exact amount of the redemption premium to be paid with respect to the 9.125% Senior
Secured Notes will not be known until shortly before the redemption date for such notes. The
redemption of notes by US Oncology will be funded by McKesson from cash and, if necessary,
borrowings by McKesson under its one-year unsecured senior bridge term loan agreement.
About McKesson
McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and
information technology company dedicated to helping its customers deliver high-quality healthcare
by reducing costs, streamlining processes, and improving the quality and safety of patient care.
Over the course of its 177-year history, McKesson has grown by providing pharmaceutical and
medical-surgical supply management across the spectrum of care; healthcare information technology
for hospitals, physicians, homecare and payers; hospital and retail pharmacy automation; and
services for manufacturers and payers designed to improve outcomes for patients. For more
information, visit www.mckesson.com.